2. Others
  3. Biochemical Assay Reagents
  4. DSPE-PEG2000-OH

DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

DSPE-PEG2000-OH

DSPE-PEG2000-OH 화학구조

사이즈 가격 재고 수량
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg   견적 받기  
500 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 publication(s) in Google Scholar

DSPE-PEG2000-OH Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE DSPE-PEG2000-OH

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity[1].

In Vitro

DSPE-PEG2000-OH (1% (w/v); 20 min) does not alter the fluidity of isolated rat lung membrane vesicles, as measured by fluorescence polarization using DPH and TMA-DPH probes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DSPE-PEG2000-OH Related Antibodies
In Vivo

DSPE-PEG-OH (0.1-2.0% (w/v); intratracheal administration; single dose) significantly enhances the pulmonary absorption of poorly absorbable macromolecules in rats, with a maximum enhancement fold of 4.5-fold for FD10 at the dose of 1.0% (w/v)[1].
DSPE-PEG-OH (0.1-1.0% (w/v); intratracheal administration; single dose; 1.0% (w/v); intratracheal administration; once weekly; for 2 consecutive weeks) does not induce significant local pulmonary membrane damage in brown rats (rats) at doses up to 1.0% (w/v), whether administered as a single intratracheal dose or once weekly for 2 consecutive weeks[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley (SD) (Male, ~250 g, ~8 weeks old)[1]
Dosage: 0.1% (w/v), 0.5% (w/v), 1.0% (w/v), 2.0% (w/v)
Administration: intrapulmonary; single dose
Result: Increased FD4 Cmax to 1.48 μg/mL, AUC0-240min to 273.34 μg·min/mL, and enhancement ratio to 1.2 at 0.1% dose; increased FD4 Cmax to 3.15 μg/mL, AUC0-240min to 511.90 μg·min/mL, and enhancement ratio to 2.2 at 0.5% dose (p < .01); increased FD4 Cmax to 9.21 μg/mL, AUC0-240min to 1013.99 μg·min/mL, and enhancement ratio to 4.3 at 1.0% dose (p < .01); increased FD4 Cmax to 7.53 μg/mL, AUC0-240min to 937.40 μg·min/mL, and enhancement ratio to 3.9 at 2.0% dose (p < .01).
Increased FD10 Cmax to 1.34 μg/mL, AUC0-240min to 228.92 μg·min/mL, and enhancement ratio to 1.8 at 0.1% dose (p < .01); increased FD10 Cmax to 2.32 μg/mL, AUC0-240min to 374.12 μg·min/mL, and enhancement ratio to 2.9 at 0.5% dose (p < .01); increased FD10 Cmax to 3.78 μg/mL, AUC0-240min to 585.89 μg·min/mL, and enhancement ratio to 4.5 at 1.0% dose (p < .01).
Increased FD70 Cmax to 0.25 μg/mL, AUC0-240min to 37.64 μg·min/mL, and enhancement ratio to 3.7 at 0.5% dose (p < .01); increased FD70 Cmax to 0.25 μg/mL, AUC0-240min to 38.43 μg·min/mL, and enhancement ratio to 3.7 at 1.0% dose (p < .01); showed no significant enhancement for FD70 at 0.1% dose.
Increased calcitonin D% to 30.21, AAC0-240min to 117.42, and enhancement ratio to 3.0 at 1.0% dose (p < .01).
Increased insulin D% to 60.19, AAC0-240min to 12.76, and enhancement ratio to 1.4 at 1.0% dose, with no statistically significant difference compared to control.
Animal Model: Sprague Dawley (SD) (Male, ~250 g, ~8 weeks old)[1]
Dosage: 0.1% (w/v), 0.5% (w/v), 1.0% (w/v) (single dose); 1.0% (w/v) (2 consecutive weekly doses)
Administration: intrapulmonary; single dose; intrapulmonary; weekly; 2 weeks
Result: Showed no obvious lung tissue damage compared to PBS control at all tested single doses, unlike positive control NaDC which caused significant tissue changes.
Exhibited no statistically significant difference in BALF protein and lactate dehydrogenase (LDH) levels compared to PBS control at 4 h post single dose administration.
Showed no statistically significant difference in BALF protein and LDH levels compared to PBS control after 2 consecutive weekly doses of 1.0% (w/v), unlike positive control NaDC which caused a dramatic increase in both markers.
분자량

2000 (Average)

Appearance

Solid

Color

White to off-white

SMILES

CCCCCCCCCCCCCCCCCC(OC[C@](OC(CCCCCCCCCCCCCCCCC)=O)([H])COP(O)(OCCNC(OCCOCCO)=O)=O)=O.[n]
선적

Room temperature in continental US; may vary elsewhere.
보관
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
용액&용해도
In Vitro: 

Ethanol : 100 mg/mL (Need ultrasonic)

  • 몰농도 계산기

  • 농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
순도&문서
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DSPE-PEG2000-OH Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DSPE-PEG2000-OHBiochemical Assay Reagentspulmonary membranespulmonary absorptionZO-1paracellular pathwaystight junction-associated proteinsratsDPHtight junction proteinsoccludinmacromoleculesInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
DSPE-PEG2000-OH
Cat. No.:
HY-140741
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.